In a study published in the Journal of Drugs in Dermatology (@JDDonline), the study authors assess the use of antihistamines and dupilumab in the treatment of alopecia areata (AA). Forty-two articles with 395 patients describe the use of antihistamines or dupilumab in AA, with the most common antihistamine regimens being oxatomide 30 mg twice per day, fexofenadine 60 or 120 mg/day, and ebastine 10 mg/day. . The majority of cases reported significant hair regrowth, decreased pruritus, and erythema. Studies on the use of dupilumab for AA demonstrated remarkable hair growth in some patients, no change in others, and no new hair loss in a patient with resolved alopecia universalis. . In contrast, dupilumab therapy for AD has been implicated as a cause of AA, drug-induced alopecia, and AA-like psoriasis. The authors conclude that the current literature is promising for the use of antihistamines as adjunct treatments for AA, while monotherapy needs to be further explored. . Visit the link in our bio to read more in #DermWorldWeekly.